musk tibetine: in contrast to other musk cpds this cpd does not cause allergic photocontact dermatitis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 67350 |
| CHEMBL ID | 3188624 |
| SCHEMBL ID | 1224154 |
| MeSH ID | M0126307 |
| Synonym |
|---|
| 5-tert-butyl-1,2,3-trimethyl-4,6-dinitrobenzene |
| benzene, 1-tert-butyl-2,6-dinitro-3,4,5-trimethyl- |
| musk tibetine |
| benzene, 1-(1,1-dimethylethyl)-2,6-dinitro-3,4,5-trimethyl- |
| ccris 7623 |
| nsc 78470 |
| einecs 205-651-6 |
| ai3-02441 |
| brn 2000732 |
| 1-tert-butyl-3,4,5-trimethyl-2,6-dinitrobenzene |
| benzene, 1-tert-butyl-3,4,5-trimethyl-2,6-dinitro- |
| 5-tert-butyl-4,6-dinitro-1,2,3-trimethylbenzene |
| benzene, 1-(1,1-dimethylethyl)-3,4,5-trimethyl-2,6-dinitro- |
| tibetene musk |
| nsc-78470 |
| benzene,4,5-trimethyl-2,6-dinitro- |
| benzene,1-dimethylethyl)-2,6-dinitro-3,4,5-trimethyl- |
| 5-tert-butyl-1,3-trimethyl-4,6-dinitrobenzene |
| nsc78470 |
| benzene,1-dimethylethyl)-3,4,5-trimethyl-2,6-dinitro- |
| benzene,6-dinitro-3,4,5-trimethyl- |
| musk tibetene |
| 145-39-1 |
| unii-cmn65165x5 |
| 3-05-00-01055 (beilstein handbook reference) |
| 2,6-dinitro-3,4,5-trimethyl-tert-butylbenzene |
| cmn65165x5 , |
| NCGC00255925-01 |
| tox21_301938 |
| dtxcid7024582 |
| dtxsid9044582 , |
| cas-145-39-1 |
| AKOS024319078 |
| FT-0629039 |
| 1-(tert-butyl)-3,4,5-trimethyl-2,6-dinitrobenzene |
| mfcd00024266 |
| SCHEMBL1224154 |
| 4,6-dinitro-5-tert-butylhemimellitene |
| MINYPECWDZURGR-UHFFFAOYSA-N |
| 1-tert-butyl-2,6-dinitro-3,4,5-trimethylbenzene |
| 1-tert-butyl-3,4,5-trimethyl-2,6-dinitrobenzene # |
| 5-t-butyl-4,6-dinitro-1,2,3-trimethylbenzene |
| CHEMBL3188624 |
| musk tibeten 10 microg/ml in cyclohexane |
| xylolmoschus |
| HY-116108 |
| benzene,1-(1,1-dimethylethyl)-3,4,5-trimethyl-2,6-dinitro- |
| Q27275538 |
| CS-0063983 |
| musk tibeten |
| AKOS040742187 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 22.4458 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 61.1306 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 16.5563 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 34.3762 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 12.4622 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 30.6379 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 57.8067 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 63.8363 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 13.6854 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.78) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (6.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||